Impact of Prevnar (PCV13) vaccine recommendations in pediatric and immunocompetent adults 65 years and older: What are the benefits and risks?
PMG Oregon Nursing Conference, 12/12/19
2000: PCV7 becomes the first FDA approved pneumococcal vaccine for pediatrics
2010: PCV13 recommended in pediatrics
2014: PCV13 recommended in immunocompetent adults 65+
2018: CDC looked at data since 2014 recommendation
2019: PCV13 now shared clinical decision-making
Women & Children
Allergy & Immunology
Watkins, James E.; Thibodeaux, Anne Marie; and Darnell, John C., "Impact of Prevnar (PCV13) vaccine recommendations in pediatric and immunocompetent adults 65 years and older: What are the benefits and risks?" (2019). Articles, Abstracts, and Reports. 2876.
Immunology and Infectious Disease Commons, Pediatrics Commons, Pharmacy and Pharmaceutical Sciences Commons